Spain· ES:1191420001
RECARBRIO 500 mg/500 mg/250 mg POLVO PARA SOLUCION PARA PERFUSION
A medicinal product containing imipenem + cilastatina + relebactam, registered in Spain by Merck Sharp & Dohme B.V..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- imipenem + cilastatina + relebactam
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imipenem + cilastatina + relebactam in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayRecarbrioMerck Sharp & Dohme B.V. (1)
- FinlandRecarbrioMerck Sharp & Dohme B.V.
- FranceRECARBRIO 500 mg/500 mg/250 mg, poudre pour solution pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomRecarbrio 500mg/500mg/250mg powder for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandRecarbrio 500 mg/500 mg/250 mg powder for solution for infusionMerck Sharp & Dohme BV,
- NetherlandsRecarbrio 500 mg/500 mg/250 mg, poeder voor oplossing voor infusieMerck Sharp & Dohme B.V.
- SwedenRecarbrio 500 mg/500 mg/250 mg Pulver till infusionsvätska, lösningMerck Sharp & Dohme BV
- CzechiaRECARBRIOMerck Sharp & Dohme B.V., Haarlem
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Recarbrio
- Liechtenstein · Recarbrio
- Norway · Recarbrio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/37fe6d1b-6cce-4758-9a0b-0f3eb135ec6b GET /v1/drugs/37fe6d1b-6cce-4758-9a0b-0f3eb135ec6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1608131252000}",
"nregistro": "1191420001",
"substance": "imipenem + cilastatina + relebactam"
}See everything about imipenem + cilastatina + relebactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.